Comparing the efficacy of medications for ADHD using meta-analysis
Stephen V Faraone1, Joseph Biederman, Thomas J Spencer
1Professor of Psychiatry; Director, Child & Adolescent Psychiatry Research, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York;
Medgenmed : Medscape General Medicine
|April 7, 2007
Summary
Comparing ADHD medications is challenging due to varied study designs. However, meta-analysis reveals significant differences in effectiveness between stimulant and non-stimulant drug classes for attention-deficit/hyperactivity disorder.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy is extensively studied.
- Direct comparative trials for ADHD medications are scarce, hindering drug comparisons.
- Variability in study design and outcome measures complicates meta-analyses.
Purpose of the Study:
- To analyze the variability of drug-placebo effect sizes in ADHD pharmacotherapy.
- To assess the influence of medication type and study design on treatment effects.
- To identify differences in medication effectiveness based on drug classes.
Main Methods:
- Conducted a meta-analysis of double-blind, placebo-controlled studies of ADHD youth published after 1979.
- Included 29 trials examining 15 different drugs and 17 outcome measures.
- Utilized meta-analysis regression to evaluate medication type and study design impacts.
Main Results:
- Short-acting stimulants, long-acting stimulants, and non-stimulants showed significant differences in effect sizes.
- Study design variables also influenced medication effects.
- Differences among the three drug classes remained significant after adjusting for study design.
Conclusions:
- Lack of uniformity in assessing medication effectiveness and study design parameters complicates direct drug comparisons.
- Effect size comparisons across studies are biased without accounting for design variability.
- Differential effects exist among broad classes of ADHD medications, allowing for class-level conclusions.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...